Skip to main content
Top
Published in: BMC Health Services Research 1/2019

Open Access 01-12-2019 | Opioids | Research article

Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial

Authors: Kim A. Hoffman, Robin Baker, Lynn E. Kunkel, Elizabeth Needham Waddell, Paula J. Lum, Dennis McCarty, P. Todd Korthuis

Published in: BMC Health Services Research | Issue 1/2019

Login to get access

Abstract

Background

The CTN-0067 CHOICES trial tests implementation of extended-release naltrexone (XR-NTX) versus treatment-as-usual (TAU) for opioid use disorders (OUD) in HIV clinics to improve HIV viral suppression. The study team investigated recruitment strategies to elucidate the barriers and facilitators to recruitment and enrollment in the study.

Main text

Methods: Semi-structured, in-depth, digitally recorded interviews were completed with study recruitment-related staff and medical providers (n = 26) from six participating HIV clinics in the fall of 2018. Interviews probed 1) factors that might prevent prospective participants from engaging in study recruitment and enrollment procedures and 2) strategies used by study staff that encourage eligible patient participation. Interviews were transcribed and thematically analyzed using a content analysis approach. Results: All respondents reported that barriers to recruitment and enrollment included challenging patient social and structural factors (e.g., homelessness or living environments with high substance use, criminal justice involvement), difficulty locating patients with unsuppressed HIV viral load and OUD within the HIV clinic, time-consuming study enrollment processes, and stigma around HIV and OUD which inhibited treatment seeking. Some respondents observed that distrust of research and researchers impeded recruitment activities in the community. A specific medication-related barrier was patient fear of opioid abstinence required prior to XR-NTX induction. Facilitators of recruitment included use of trusted peer outreach/recruitment workers in the community, hospitalizations that offered windows of opportunities for screening and XR-NTX induction, providing participant transportation, and partnerships with harm reduction organizations for referrals.

Conclusions

Though study personnel encountered barriers to recruitment in the CHOICES study, persons with untreated HIV and OUD can be enrolled in multisite clinical trials by using enhanced recruitment strategies that extend outside of the HIV clinic. Employing peer outreach workers and collaborating with syringe service programs may be especially helpful in facilitating recruitment and merit inclusion in similar study protocols.
Literature
6.
go back to reference Chaudhry, A. A., Botsko, M., Weiss, L., Egan, J. E., Mitty, J., Estrada, B., … BHIVES Collaborative. (2011). Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr (1999), 56 Suppl 1, S14–S21. https://doi.org/https://doi.org/10.1097/QAI.0b013e318209d3b9.CrossRef Chaudhry, A. A., Botsko, M., Weiss, L., Egan, J. E., Mitty, J., Estrada, B., … BHIVES Collaborative. (2011). Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr (1999), 56 Suppl 1, S14–S21. https://​doi.​org/​https://​doi.​org/​10.​1097/​QAI.​0b013e318209d3b9​.CrossRef
8.
go back to reference Stein MD, Hanna L, Natarajan R, Clarke J, Marisi M, Sobota M, et al. Alcohol use patterns predict high-risk HIV behaviors among active injection drug users. J Subst Abus Treat. 2000;18(4):359–63.CrossRef Stein MD, Hanna L, Natarajan R, Clarke J, Marisi M, Sobota M, et al. Alcohol use patterns predict high-risk HIV behaviors among active injection drug users. J Subst Abus Treat. 2000;18(4):359–63.CrossRef
9.
go back to reference Andersen R, Bozzette S, Shapiro M, St Clair P, Morton S, Crystal S, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS consortium. HIV Cost and Services Utilization Study Health Services Research. 2000;35(2):389–416.PubMed Andersen R, Bozzette S, Shapiro M, St Clair P, Morton S, Crystal S, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS consortium. HIV Cost and Services Utilization Study Health Services Research. 2000;35(2):389–416.PubMed
10.
go back to reference Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83–8.CrossRef Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83–8.CrossRef
13.
go back to reference Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, Kalichman MO, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med. 2013;28(3):399–405. https://doi.org/https://doi.org/10.1007/s11606-012-2231-1.CrossRef Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, Kalichman MO, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med. 2013;28(3):399–405. https://​doi.​org/​https://​doi.​org/​10.​1007/​s11606-012-2231-1.CrossRef
14.
go back to reference Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–420. https://doi.org/https://doi.org/10.1093/aje/kwj059.CrossRef Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163(5):412–420. https://​doi.​org/​https://​doi.​org/​10.​1093/​aje/​kwj059.CrossRef
16.
go back to reference Mathews WC, McCutchan JA, Asch S, Turner BJ, Gifford AL, Kuromiya K, et al. National estimates of HIV-related symptom prevalence from the HIV cost and services utilization study. Med Care. 2000;38(7):750–62.CrossRef Mathews WC, McCutchan JA, Asch S, Turner BJ, Gifford AL, Kuromiya K, et al. National estimates of HIV-related symptom prevalence from the HIV cost and services utilization study. Med Care. 2000;38(7):750–62.CrossRef
18.
go back to reference Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005;43(9 Suppl):III40–52.PubMed Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005;43(9 Suppl):III40–52.PubMed
19.
go back to reference Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcohol Clin Exp Res. 2005;29(3):389–94.CrossRef Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Substance abuse treatment and hospitalization among a cohort of HIV-infected individuals with alcohol problems. Alcohol Clin Exp Res. 2005;29(3):389–94.CrossRef
20.
go back to reference Korthuis, P. Todd, Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., … BHIVES Collaborative. (2011). Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. Journal of Acquired Immune Deficiency Syndromes (1999), 56 Suppl 1, S39–45. https://doi.org/https://doi.org/10.1097/QAI.0b013e318209754c.CrossRef Korthuis, P. Todd, Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., … BHIVES Collaborative. (2011). Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. Journal of Acquired Immune Deficiency Syndromes (1999), 56 Suppl 1, S39–45. https://​doi.​org/​https://​doi.​org/​10.​1097/​QAI.​0b013e318209754c​.CrossRef
21.
go back to reference Altice, F. L., Bruce, R. D., Lucas, G. M., Lum, P. J., Korthuis, P. T., Flanigan, T. P., … BHIVES Collaborative. (2011). HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (1999), 56 Suppl 1, S22–S32. https://doi.org/https://doi.org/10.1097/QAI.0b013e318209751e.CrossRef Altice, F. L., Bruce, R. D., Lucas, G. M., Lum, P. J., Korthuis, P. T., Flanigan, T. P., … BHIVES Collaborative. (2011). HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (1999), 56 Suppl 1, S22–S32. https://​doi.​org/​https://​doi.​org/​10.​1097/​QAI.​0b013e318209751e​.CrossRef
23.
go back to reference Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet, 391(10118), 309–318. https://doi.org/https://doi.org/10.1016/S0140-6736(17)32812-X.CrossRef Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet, 391(10118), 309–318. https://​doi.​org/​https://​doi.​org/​10.​1016/​S0140-6736(17)32812-X.CrossRef
24.
go back to reference Korthuis, Philip T., Lum, P. J., Vergara-Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., … CTN-0055 CHOICES Investigators. (2017). Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction, 112(6), 1036–1044. https://doi.org/https://doi.org/10.1111/add.13753.CrossRef Korthuis, Philip T., Lum, P. J., Vergara-Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., … CTN-0055 CHOICES Investigators. (2017). Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction, 112(6), 1036–1044. https://​doi.​org/​https://​doi.​org/​10.​1111/​add.​13753.CrossRef
25.
go back to reference Nichols C, Kunkel LE, Baker R, Jelstrom E, Addis M, Hoffman KA, et al. Use of single IRBs for multi-site studies: a case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. Contemporary Clinical Trials Communications. 2019;100319. https://doi.org/https://doi.org/10.1016/j.conctc.2019.100319.CrossRef Nichols C, Kunkel LE, Baker R, Jelstrom E, Addis M, Hoffman KA, et al. Use of single IRBs for multi-site studies: a case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. Contemporary Clinical Trials Communications. 2019;100319. https://​doi.​org/​https://​doi.​org/​10.​1016/​j.​conctc.​2019.​100319.CrossRef
26.
go back to reference Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research; 1967. Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research; 1967.
27.
go back to reference Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. HIV viral suppression trends over time among HIV-infected patients receiving Care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376–384. https://doi.org/https://doi.org/10.7326/M17-2242.CrossRef Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. HIV viral suppression trends over time among HIV-infected patients receiving Care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376–384. https://​doi.​org/​https://​doi.​org/​10.​7326/​M17-2242.CrossRef
Metadata
Title
Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial
Authors
Kim A. Hoffman
Robin Baker
Lynn E. Kunkel
Elizabeth Needham Waddell
Paula J. Lum
Dennis McCarty
P. Todd Korthuis
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2019
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-019-4721-x

Other articles of this Issue 1/2019

BMC Health Services Research 1/2019 Go to the issue